Manages well-differentiated thyroid cancer Thyroid Suppression Test. ANDA 200295, held by Sigmapharm Labs LLC. Liothyronine Sodium.
As of Nov 16, 2026, ANDA 200295 (Liothyronine Sodium), held by Sigmapharm Labs LLC, was first approved by FDA on Nov 29, 2012, with 3 approved supplements and 0 published complete response letters.
LIOMNY is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 29, 2012 | Original application | Approved | None posted |
| Liothyronine SodiumEQ 0.005MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Liothyronine SodiumEQ 0.025MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Liothyronine SodiumEQ 0.05MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Aug 1, 2025 | Supplement 10Manufacturing · Standard review | Approved | None posted |
| Jun 12, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 23, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 29, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters